JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
Interest Income Expense
JW (Cayman) Therapeutics Co Ltd
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
Interest Income Expense
¥21.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Interest Income Expense
-¥1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Interest Income Expense
-¥67.8m
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Interest Income Expense
¥217.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
134%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Interest Income Expense
-¥41.7m
|
CAGR 3-Years
33%
|
CAGR 5-Years
-84%
|
CAGR 10-Years
N/A
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Interest Income Expense
¥100.8m
|
CAGR 3-Years
126%
|
CAGR 5-Years
96%
|
CAGR 10-Years
N/A
|
See Also
What is JW (Cayman) Therapeutics Co Ltd's Interest Income Expense?
Interest Income Expense
21.6m
CNY
Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Interest Income Expense amounts to 21.6m CNY.